JP Morgan Maintains Overweight on Privia Health Gr, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains an Overweight rating on Privia Health Group (PRVA) but lowers the price target from $38 to $30.

March 06, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Privia Health Group but lowers the price target from $38 to $30.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price potential, the maintenance of an Overweight rating indicates a continued positive long-term view on the company by JP Morgan. This mixed signal could lead to neutral short-term price movement as investors digest both the positive rating and the lowered price expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100